Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1998048784) METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1998/048784 International Application No.: PCT/US1998/008463
Publication Date: 05.11.1998 International Filing Date: 28.04.1998
Chapter 2 Demand Filed: 24.11.1998
IPC:
A61K 31/138 (2006.01) ,A61K 31/277 (2006.01) ,A61K 31/352 (2006.01) ,A61K 31/4045 (2006.01) ,A61K 31/407 (2006.01) ,A61K 31/46 (2006.01) ,A61K 31/473 (2006.01) ,A61K 31/475 (2006.01) ,A61K 31/49 (2006.01) ,A61K 31/5415 (2006.01) ,A61K 38/13 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
13
Amines, e.g. amantadine
135
having aromatic rings, e.g. methadone
138
Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
275
Nitriles; Isonitriles
277
having a ring, e.g. verapamil
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
35
having six-membered rings with one oxygen as the only ring hetero atom
352
condensed with carbocyclic rings, e.g. cannabinols, methantheline
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403
condensed with carbocyclic rings, e.g. carbazole
404
Indoles, e.g. pindolol
4045
Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
407
condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
46
8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
473
ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
475
having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
49
Cinchonan derivatives, e.g. quinine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
54
having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
5415
ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
12
Cyclic peptides
13
Cyclosporins
Applicants:
THE UNIVERSITY OF BRITISH COLUMBIA [CA/CA]; 2255 Westbrook Mall Vancouver, British Columbia V6T 1Z3, CA (AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BY, CA, CF, CG, CH, CI, CM, CN, CU, CY, CZ, DE, DK, EE, ES, FI, FR, GA, GB, GE, GH, GM, GN, GR, GW, HU, ID, IE, IL, IS, IT, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MC, MD, MG, MK, ML, MN, MR, MW, MX, NE, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SN, SZ, TD, TG, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW)
REINER, Peter, B. [US/CA]; CA (UsOnly)
LAM, Fred, Chiu-lai [CA/CA]; CA (UsOnly)
Inventors:
REINER, Peter, B.; CA
LAM, Fred, Chiu-lai; CA
Agent:
HANLEY, Elizabeth, A. ; Lahive & Cockfield, LLP 28 State Street Boston, MA 02109, US
Priority Data:
08/847,61628.04.1997US
Title (EN) METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS
(FR) METHODES ET COMPOSITION DE MODULATION DE L'AMYLOIDOSE
Abstract:
(EN) Methods for modulating amyloid deposition in a subject are described. An effective amount of at least one ATP binding cassette (ABC) transporter blocker is administered to a subject, such that modulation of amyloid deposition occurs. Methods also include administering an effective amount of at least one ABC transporter blocker, or a pharmaceutically acceptable salt thereof, to a subject such that a disease state associated with amyloidosis is treated. Packaged pharmaceutical compositions for treating amyloidosis are described. The package includes a container for holding an effective amount of a pharmaceutical composition and instructions for using the pharmaceutical composition for treatment of amyloidosis. The pharmaceutical composition includes at least one ABC blocker for modulating amyloid deposition in a subject. Methods for identifying agent which modulate amyloid deposition in a subject are also described. An effective amount of at least one ATP binding cassette (ABC) transporter blocker is administered to an organism, such that modulation of amyloid deposition occurs.
(FR) L'invention concerne des méthodes permettant de moduler le dépôt amyloïde chez un sujet. On administre au sujet une dose efficace d'au moins un inhibiteur de transporteur de cassette de liaison d'ATP (ABC), de manière à moduler le dépôt amyloïde. Ces méthodes consistent également à administrer au sujet une dose efficace d'au moins un inhibiteur de transporteur d'ABC ou d'un de ses sels pharmaceutiquement acceptables, de manière à traiter un état pathologique associé à l'amyloïdose. L'invention concerne aussi des compositions pharmaceutiques conditionnées permettant de traiter l'amyloïdose. Le conditionnement comprend un contenant destiné à renfermer une dose efficace d'une composition pharmaceutique ainsi que les instructions d'utilisation de ladite composition pour le traitement de l'amyloïdose. La composition pharmaceutique renferme au moins un inhibiteur d'ABC pour moduler le dépôt amyloïde chez un sujet. L'invention a en outre pour objet des procédés d'identification d'agents modulant le dépôt amyloïde chez un sujet. On administre à un organisme une dose efficace d'au moins un inhibiteur de transporteur d'ABC de manière à moduler le dépôt amyloïde.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
IL132169EP0979086JP2002504895 CA2285948AU1998072603